The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1632
ISSUE1632
September 6, 2021
Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis
September 6, 2021 (Issue: 1632)
The FDA has approved ibrexafungerp (Brexafemme –
Scynexis), a first-in-class triterpenoid antifungal
("fungerp"), for oral treatment of vulvovaginal candidiasis
in postmenarchal females.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.